CRDF
Cardiff Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.09
+0.93%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$84.80M
MomentumView details →
1D Return
+0.93%
YTD Return
−61.39%
RSI (14)
59.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$84.80M
RSI (14)
59.9
MomentumView details →
1D Return
+0.93%
YTD Return
−61.39%
SummaryUpdated Jun 1, 2026
Cardiff Oncology, Inc. (NASDAQ:CRDF) is a clinical-stage biotechnology company founded in 1999 and headquartered in San Diego, California. Originally incorporated as Trovagene, Inc., the company changed its name to Cardiff Oncology in May 2012 to reflect its focused mission on developing innovative cancer treatments. The company went public in 2004 and has since dedicated itself to advancing novel therapeutic approaches for cancer patients, with a particular emphasis on targeting specific molecular pathways that drive tumor growth and resistance to existing treatments.
Similar companies
Latest newsMore news →
Cardiff Oncology presented positive Phase 2 CRDF-004 data at ASCO supporting advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into a planned registrational program for first-line RAS-mutated metastatic colorectal cancer.24d agoCardiff Oncology entered into definitive agreements for a registered direct offering of shares of its common stock and warrants.51d ago